-
公开(公告)号：US20230065827A1
公开(公告)日：2023-03-02
申请号：US17791027
申请日：2020-11-19
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG , Paul Michael SCOLA , Zhongxing ZHANG
Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-
公开(公告)号：US20200172578A1
公开(公告)日：2020-06-04
申请号：US16624989
申请日：2018-06-21
Applicant: Bristol-Myers Squibb Company
Inventor： Kevin W. GILLMAN , Jason GOODRICH , Li-Qiang SUN , Eric MULL , David R. LANGLEY , Paul Michael SCOLA
IPC: C07K7/56
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 pro-tein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20220389061A1
公开(公告)日：2022-12-08
申请号：US17772343
申请日：2020-10-29
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG , Paul Michael SCOLA , Zhongxing ZHANG
Abstract: In accordance with the present disclosure, macrocyclic compounds have been discovered that bind to PD-L1 and are capable of inhibiting the interaction of PD-L1 with PD-1 and CD80. These macrocyclic compounds exhibit in vitro immunomodulatory efficacy thus making them therapeutic candidates for the treatment of various diseases including cancer and infectious diseases.
-
公开(公告)号：US20200216498A1
公开(公告)日：2020-07-09
申请号：US16711105
申请日：2019-12-11
Applicant: Bristol-Myers Squibb Company
Inventor： Kevin W. GILLMAN , Jason GOODRICH , Kenneth M. BOY , Yunhui ZHANG , Claudio MAPELLI , Michael A. POSS , Paul Michael SCOLA , David R. LANGLEY , Nicholas A. MEANWELL
Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20230242585A1
公开(公告)日：2023-08-03
申请号：US17998137
申请日：2021-05-07
Applicant: Bristol-Myers Squibb Company
Inventor： Tao WANG , Paul Michael SCOLA , Zhongxing ZHANG
IPC: C07K7/54
Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PDL 1 and PD-L 1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
Patent Agency Ranking
公开(公告)号：US20210094932A1
公开(公告)日：2021-04-01
申请号：US16977374
申请日：2019-02-28
Applicant: Bristol-Myers Squibb Company
Inventor： Kap-Sun YEUNG , Denis R. ST. LAURENT , David R. LANGLEY , Paul Michael SCOLA
IPC: C07D401/12 , C07D401/14 , C07D213/85
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20200181125A1
公开(公告)日：2020-06-11
申请号：US16499009
申请日：2018-03-26
Applicant: Bristol-Myers Squibb Company
Inventor： Kap-Sun YEUNG , Denis R. ST. LAURENT , Jeffrey Lee ROMINE , Paul Michael SCOLA
IPC: C07D405/14 , C07D405/12 , C07D401/14 , C07D401/12
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various pp diseases, including cancer and infectious diseases. (I)
-
公开(公告)号：US20240124417A1
公开(公告)日：2024-04-18
申请号：US17766483
申请日：2020-10-01
Applicant: Bristol-Myers Squibb Company
Inventor： Kap-Sun YEUNG , Denis R. ST. LAURENT , Li-Qiang SUN , Zhiwei YIN , Katharine A. GRANT-YOUNG , Paul Michael SCOLA
IPC: C07D401/14 , A61K31/4439 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , C07D401/12 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D513/04
CPC classification number: C07D401/14 , A61K31/4439 , A61K31/4545 , A61K31/497 , A61K31/501 , A61K31/506 , C07D401/12 , C07D403/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D513/04
Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20230101323A1
公开(公告)日：2023-03-30
申请号：US17725340
申请日：2022-04-20
Applicant: Bristol-Myers Squibb Company
Inventor： Kevin W. GILLMAN , Jason GOODRICH , Kenneth M. BOY , Yunhui ZHANG , Claudio MAPELLI , Michael A. POSS , Paul Michael SCOLA , David R. LANGLEY , Nicholas A. MEANWELL
Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
公开(公告)号：US20190322704A1
公开(公告)日：2019-10-24
申请号：US16462508
申请日：2017-11-06
Applicant: Bristol-Myers Squibb Company
Inventor： Kevin W. GILLMAN , Jason GOODRICH , David R. LANGLEY , Paul Michael SCOLA
Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
-
-
-
-
-
-
-
-
Search Results
16
records
(took 0.019 seconds)
